Released Mar 18, 2019, before the open
10-K filed Mar 18, 2019, 77 days after period end · 0001144204-19-014464
Q4 2018 · 10-K
Revenue$27.02M$27.02M derived+527.6% vs Q4 2017+3,975.1% vs Q3 2018
Net Income-$5.43M-$5.43M N/M vs Q4 2017N/M vs Q3 2018
EPS Diluted-$0.40-$0.40 no prior Q4 2017 on fileN/M vs Q3 2018
Operating Income-$3,672,000N/M
Operating Cash Flowderived-$4,004,000N/M
Free Cash Flowderived-$4,192,000N/M
Margins · derived
Operating margin-13.6%+209.0 pt vs Q4 2017
Net margin-20.1%+288.9 pt vs Q4 2017
What the release said
The release
Same quarter
| Metric | Q4 2018 | Q4 2017dderived from reported figures | Q4 2016dderived from reported figures | Q4 2015dderived from reported figures |
|---|---|---|---|---|
| Revenue | $27.02M | $4.31M | $2.08M | $0.00 |
| Net Income | -$5.43M | -$13.31M | -$2.62M | $72.90M |
| EPS Diluted | -$0.40 | — | — | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR